Fennec Pharmaceuticals Q1 2024 GAAP EPS $0.41 Beats $0.26 Estimate, Sales $25.377M Beat $18.876M Estimate
Fennec Pharmaceuticals Q1 2024 GAAP EPS $0.41 Beats $0.26 Estimate, Sales $25.377M Beat $18.876M Estimate
Fennec Pharmicals 2024年第一季度GAAP每股收益0.41美元超過預期的0.26美元，銷售額爲2537.7萬美元，超過預期的1887.6萬美元
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.26 by 57.69 percent. This is a 278.26 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $25.377 million which beat the analyst consensus estimate of $18.876 million by 34.44 percent. This is a 1.41K percent increase over sales of $1.677 million the same period last year.
Fennec Pharmicals（納斯達克股票代碼：FENC）公佈的季度收益爲每股0.41美元，比分析師普遍預期的0.26美元高出57.69％。這比去年同期每股虧損0.23美元（0.23美元）增長了278.26％。該公司公佈的季度銷售額爲253.77億美元，比分析師共識估計的1887.6萬美元高出34.44％。這比去年同期的167.7萬美元銷售額增長了141萬個百分點。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。